Survodutide vs Wegovy: Dual-Hormone Newcomer vs Approved Semaglutide

Survodutide and Wegovy both act on the GLP-1 system, but survodutide adds a second hormone target and takes aim at liver disease as well as weight. In its phase 3 trial, survodutide produced about 16.6% weight loss, modestly ahead of Wegovy’s roughly 15%, along with notable reductions in liver and visceral fat. The key difference is availability: survodutide is investigational and not approved, while Wegovy is FDA-approved and can be prescribed today, including through TrimRx. Here’s the full comparison.

How They Work

Wegovy is semaglutide, a GLP-1 receptor agonist that reduces appetite and slows stomach emptying. It’s a weekly injection with a long track record for weight loss, and it also carries approvals for cardiovascular risk reduction and, more recently, for a form of fatty liver disease.

Survodutide is a dual agonist, activating both the GLP-1 and glucagon receptors. The glucagon component appears to drive extra fat metabolism, particularly in the liver, which is why survodutide is being studied heavily for MASH (a serious fatty liver condition) in addition to obesity. It’s also given as a weekly injection.

How They Compare on Results

Survodutide’s phase 3 data arrived recently. In the SYNCHRONIZE-1 trial published in the New England Journal of Medicine in 2026, survodutide produced up to about 16.6% average weight loss over 76 weeks, along with reductions of up to 34% in visceral fat and 63% in liver fat. Wegovy, in its STEP 1 trial, produced roughly 15% weight loss. So survodutide holds a modest edge on weight, with a distinct advantage on liver-related measures.

Why Availability Is the Deciding Factor

Survodutide’s results are encouraging, especially its liver benefits, but it remains investigational. Its phase 3 obesity program is still ongoing, and it has not been submitted for or granted FDA approval, so it cannot be prescribed. Even in a best case, availability would be some time off.

Wegovy is available now. Its weight-loss results are well established, it has additional approvals for heart and liver conditions, and TrimRx prescribes semaglutide in both compounded and brand-name forms. For someone who wants effective, proven treatment today, that settles much of the comparison.

Consider a hypothetical patient with excess weight and early fatty liver who finds survodutide’s liver data appealing. Since survodutide isn’t available, the practical option is to start an approved medication now, and semaglutide already carries a fatty liver approval of its own. You can explore what fits you through the TrimRx quiz, and if you want to size up the service first, there’s an honest review of how it works.

Frequently Asked Questions

Is survodutide better than Wegovy?

Survodutide produced slightly more weight loss in trials (about 16.6% versus 15%) and showed strong liver and visceral fat reductions. But survodutide is investigational and unavailable, while Wegovy is approved and can be prescribed now.

What makes survodutide different?

Survodutide activates the glucagon receptor in addition to GLP-1, which appears to boost fat metabolism, especially in the liver. That’s why it’s being studied for fatty liver disease as well as obesity.

Can I get Wegovy through TrimRx?

Yes. TrimRx prescribes semaglutide (the drug in Wegovy) in both compounded and brand-name forms, after a licensed provider reviews your health profile.

To see whether semaglutide fits your situation, you can take the TrimRx quiz for a licensed provider’s review.

This article is for educational purposes and is not medical advice. Survodutide is investigational and not FDA-approved or available. Trial figures are preliminary and may change. Consult a qualified healthcare provider. Individual results vary.